Hormonal Regulation FDA Approved

PT-141

Also known as: Bremelanotide

Molecular Identifiers

Molecular Formula

C50H68N14O10

CAS Number

189691-06-3

PubChem CID

9941379

Molecular Weight

1025.2 Da

Overview

Melanocortin MC4R receptor agonist. Research in sexual function. Effects last 6-12 hours. On-demand use.

FDA-approved in 2019 as Vyleesi® (bremelanotide) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. MC4R agonist with a central mechanism of action, independent of the vascular system.

Extended notation: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Cyclic peptide with non-natural amino acids

Half-life

~2-3 hours

Administration Route

Subcutaneous

Mechanism of Action

Selective MC4R receptor agonism in the CNS
Activation of central dopaminergic pathways
Vascular system-independent effect (unlike PDE5 inhibitors)

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter	Value
Dose	500-2000 mcg per injection
Frequency	As needed, maximum 2-3x/week
Timing	1-2 hours before desired effect
Duration	On-demand use

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

Nausea
Facial flushing
Headache
Transient blood pressure increase

Product Properties

Purity	>99%
Appearance	White lyophilized powder
Solubility	Soluble in water and bacteriostatic water
Source	Solid-phase peptide synthesis (SPPS). Contains lactam bridge (cyclic structure).
Storage	Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles.